Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?

Nanomedicine

Volumn 7, Issue 3, 2012, Pages 365-382

  Tosi, Giovanni ^a   Badiali, Luca ^a   Ruozi, Barbara ^a   Vergoni, Anna Valeria ^a   Bondioli, Lucia ^a   Ferrari, Anna ^a   Rivasi, Francesco ^a   Forni, Flavio ^a   Vandelli, Maria Angela ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

blood brain barrier crossing; brain targeting; in vivo experiments; leptin; nanoparticles; sequence 12 32

Indexed keywords

LEPTIN; LEPTIN[12-32]; NANOPARTICLE; POLYGLACTIN; TETRAMETHYLRHODAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHEMICAL MODIFICATION; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; FOOD INTAKE; MALE; MEMBRANE PERMEABILITY; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; RAT; SURFACE PROPERTY; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; LEPTIN; MALE; NANOPARTICLES; PARTICLE SIZE; POLYGLACTIN 910; RATS; RATS, WISTAR; SURFACE PROPERTIES;

EID: 84857848616     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.98     Document Type: Article

References (53)

1. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Exp. Opin. Drug Deliv. 5, 155-174 (2008).
2. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 14, 97-105 (2006).
3. Calvo JP, Gouritin B, Chacun H et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157-1166 (2001). Application of surface engineering of nanoparticulate systems for long circulation aim.
4. Tosi G, Costantino L, Rivasi F et al. Targeting the central nervous system: in vivo experiments with peptide derivatized nanoparticles loaded with Loperamide and Rhodamine 123. J. Control. Rel. 122, 1-9 (2007). Application of glycopeptide surface engineering of polymeric nanoparticles for blood-brain barrier (BBB) crossing: proof of concepts.
5. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J. Control. Rel. 93, 271-282 (2003).
6. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. USA 93, 14164-14169 (1996). Application of immune liposomes for brain delivery.
7. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Rel. 137, 78-86 (2009). One of the first papers dealing with electron microscopy analysis and evidence of the BBB crossing mechanism by nanoparticulate systems.
8. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control. Rel. 108, 84-96 (2005).
9. Tosi G, Vergoni AV, Ruozi B et al. Sialic-acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control. Rel. 145, 49-57 (2010).
10. Nobs L, Buchegger F, Gurny R, Allémann E. Poly(lactic)-acid nanoparticles labeled with biologically active NeutrAvidine for active targeting. Eur. J. Pharm. Biopharm. 58, 483-490 (2004).
11. Nobs L, Buchegger F, Gurny R, Allémann E. Surface modification of poly (lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int. J. Pharm. 250, 327-337 (2003).
12. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25 (2010).
13. Gabathuler R. Approaches to transport therapeutic drugs across the blood brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48-57 (2010). Good review on the possible approaches for BBB crossing and CNS delivery: comments and criticism.
14. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX-26 conjugated-liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24, 1193-1204 (2004).
15. Karatas H, Aktas Y, Gursoy-Ozdemir Y et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci. 29, 13761-13769 (2009).
16. Corp S, Conze DB, Smith F, Campfield LA. Regional localization of specific [125]leptin binding sites in rat forebrain. Brain Res. 789, 40-47 (1998).
17. Burguera B, Couce ME. Leptin access into the brain: A saturated mechanism in obesity. Phys. Behav. 74, 717-720 (2001).
18. Biobaek C, Elmquist JK, Michl P et al. Expression of leptin receptor isoforms in rat microvessels. Endocrinology 139, 3485-3491 (1998).
19. Belouzard S, Rouillé Y. Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis. EMBO J. 25, 932-942 (2006).
20. Tu H, Pan W, Feucht L, Kastin AJ. Convergent trafficking pattern of leptin afer endocytosis mediated by ObRa-ObRb. J. Cell. Phys. 212, 215-222 (2007).
21. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 29, 1263-1271 (1995).
22. Chelikani PK, Glimm DR, Kennelly JJ. Tissue distribution of Leptin and Leptin receptor mRNA in the bovine. J. Dairy Sci. 86, 2369-2372 (2003).
23. Iserentat H, Peelman F, Defeau D, Vandekerckhove J, Zabeau L, Tavernier J. Mapping of the interface between leptin and the leptin receptor CRH2 domain. J. Cell Sci. 118, 2519-2527 (2005).
24. Otvos L, Terrasi M, Cascio S et al. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta 1783, 1745-1754 (2008).
25. Grasso P, Leinung MC, Ingher SP, Lee DW. In vivo effects of leptin-related synthetic peptides on body weight and food intake in femal ob/ob mice: localization of leptin activity to domains between aminoacid residues 106-140. Endocrinology 138, 1413-1418 (1997)
26. Grasso P, Leinung MC, Lee DW. Epitope mapping of secreted mouse leptin utilizing peripherally administered synthetic peptides. Regul. Pept. 85, 93-100 (1999).
27. Barrett GL, Trieu J, Naim T. The identification of leptin-derived peptides that are taken up the brain. Regul. Pept. 155, 55-61 (2009). Study on leptin fragments able to interact with the BBB transporter and possible application in drug delivery across the BBB.
28. Liu Y, Li J, Shao K et al. A leptin derived 30-amino-acid peptide modified PEGylated poly-l-lysine dendrigraft for brain targeted gene delivery. Biomaterials 19, 5246-5257 (2010).
29. Tamaru M, Akita H, Fujiwara T, Kajimoto K, Harashima H. Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem. Biophys. Res. Comm. 394, 587-592 (2010).
30. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm. 43, 287-294 (1997).
31. Joshi DP, Lan-Chun-Fung YL, Pritchard JW. Determination of poly (vinyl alcohol) via its complex with boric acid and iodine. Anal. Chim. Acta 104, 153-160 (1979).
32. Tosi G, Bondioli L, Ruozi B et al. NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. J. Neural. Transm. 118, 145-153 (2011).
33. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine 5, 369-377 (2009). Biodistribution of glycopeptides engineered nanoparticles for brain delivery.
34. Xu Z, Pilch DS, Srinivasan AR, Olson WK, Geacintov NE, Breslauer KJ. Modulation of nucleic acid structure by ligand binding induction of a DNA·RNA·DNA hybrid triplex by DAPI intercalation. Bioorg. Med. Chem. 5, 1137-1147 (1997).
35. Reynold ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy, J. Cell. Biol. 17, 208-212 (1963).
36. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54, 1882-1888 (1990).
37. Sugimoto Y, Yamada J, Yoshikawa T, Noma T, Horisaka K. Effects of peripheral 5-HT2 and 5-HT3 receptor agonists on food intake in food-deprived and 2-deoxy-d-glucose-treated rats. Eur. J. Pharmacol. 36, 15-21 (1996).
38. Zambaux MF, Bonneaux F, Gref R et al. Influence of experimental parameters on the characteristics of poly(lactic-acid) nanoparticles prepared by double emulsion method. J. Control. Rel. 50, 31-40 (1998).
39. Van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J. Control. Rel. 150(1), 30-36 (2011). Extremely good with details dealing with in vivo comparison of several ligands, conjugated to liposomes, for BBB crossing.
40. Van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. In vivo methods to study uptake of nanoparticles into the brain. Pharm. Res. 28(3), 456-471 (2011).
41. Schnyder A, Krähenbühl S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Targ. 13, 325-335 (2005).
42. Huwyler J, Yan J, Pardridge WM. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharm. Exp. Ther. 282, 1541-1546 (1997).
43. Lode J, Fichtner I, Kreuter J, Berndt A, Diederichs JE, Reszka R. Influence of surface-modifying surfactants on the pharmacokinetic behaviour of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res. 18, 1613-1619 (2001).
44. Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood brain barriers. Biotechnol. Bioeng. 99, 475-484 (2008).
45. Zhang Y, Pardridge WM. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm. Res. 26, 1059-1063 (2008).
46. Zhang Y, Wang Y, Boado RJ, Pardridge WM. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm. Res. 25, 400-406 (2008).
47. Zhang Y, Schlachetzki F, Pardridge WM. Global non viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7, 11-18 (2003). Demonstration of pharmacological efficacy of liposome-mediated delivery for gene transfer.
48. Tosi G, Fano RA, Bondioli L et al. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond.) 6(3), 423-436 (2011). Electron microscopy and computational analysis evidences of BBB crossing after in vivo administration of polymeric glycopeptide-engineered nanoparticles.
49. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs, Biomaterials. 29, 4429-4438 (2008).
50. Banks W. Developing drugs that can cross the blood-brain barrier: Applications to Alzheimer's disease. BMC Neurosci. 9(Suppl 3), S2 (2008).
51. Morrison CD, Morton GJ, Niswender KD, Gelling RW, Schwartz MW. Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am. J. Physiol. Endocrinol. Metab. 289, E1051-E1057 (2005).
52. Jethwa PH, Smith KL, Small CJ et al. Neuromedin U partially mediates leptin-induced hypothalamo-pituitary adrenal (HPA) stimulation and has a physiological role in the regulation of the HPA axis in the rat. Endocrinology 147, 2886-2892 (2006).
53. Ambati S, Duan J, Duff E et al. Gene expression in arcuate nucleus-median eminence of rats treated with leptin or ciliary neurotrophic factor. Biofactors 31, 133-144 (2007).